Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALBERTO BESSUDO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1003888074
CMS profile
226877
Location
ENCINITAS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,923.74

152 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,875.33 149
Education $48.41 3

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALBERTO BESSUDO

NPI 1003888074 · CMS profile ID 226877

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ENCINITAS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003888074?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003888074?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003888074?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1003888074?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

152 matching records · $3,923.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 152 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 152.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $19.3005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933983 CMS
Novartis Pharmaceuticals Corporation $28.2205/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200118322 CMS
Celgene Corporation $32.7005/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933987 CMS
E.R. Squibb & Sons, L.L.C. $23.3305/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933989 CMS
PFIZER INC. $18.7305/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229132585 CMS
ACCORD HEALTHCARE, INC. $22.4005/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248752504 CMS
ARRAY BIOPHARMA INC $25.9305/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229213012 CMS
Gilead Sciences, Inc. $14.6205/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234574076 CMS
E.R. Squibb & Sons, L.L.C. $27.9305/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933977 CMS
Novartis Pharmaceuticals Corporation $17.4205/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200118320 CMS
Eisai Inc. $26.4505/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244457399 CMS
PFIZER INC. $14.9305/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229213004 CMS
ABBVIE INC. $20.1005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201510078 CMS
Exelixis Inc. $23.0705/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218790245 CMS
PFIZER INC. $22.2704/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229238228 CMS
PFIZER INC. $20.0704/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228931931 CMS
Coherus Oncology, Inc. $22.5604/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235235604 CMS
Eisai Inc. $24.4404/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244457397 CMS
Gilead Sciences, Inc. $26.1404/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234464913 CMS
Exelixis Inc. $35.3904/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218790247 CMS
Syndax Pharmaceuticals, Inc. $27.4704/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238989946 CMS
Novartis Pharmaceuticals Corporation $27.9904/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200118310 CMS
Exelixis Inc. $27.4504/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218790249 CMS
Alexion Pharmaceuticals, Inc. $29.2604/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202969592 CMS
GENZYME CORPORATION $121.0104/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233275205 CMS
E.R. Squibb & Sons, L.L.C. $15.0903/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933975 CMS
BeOne Medicines USA, Inc. $23.8303/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202901246 CMS
E.R. Squibb & Sons, L.L.C. $19.5503/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933941 CMS
Exelixis Inc. $17.8903/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218790251 CMS
ABBVIE INC. $24.4603/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201510076 CMS
Cumberland Pharmaceuticals, Inc. $13.5003/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242137507 CMS
Daiichi Sankyo Inc. $20.7203/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197046751 CMS
Novartis Pharmaceuticals Corporation $18.5003/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200118308 CMS
E.R. Squibb & Sons, L.L.C. $15.0803/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933943 CMS
Celgene Corporation $21.1003/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933951 CMS
SOBI, INC $25.1003/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240224308 CMS
Merck Sharp & Dohme LLC $15.7203/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238149916 CMS
Daiichi Sankyo Inc. $20.1703/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197052409 CMS
Sumitomo Pharma America, Inc. $24.0603/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176603184 CMS
SOBI, INC $29.5302/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240224304 CMS
E.R. Squibb & Sons, L.L.C. $28.4502/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933933 CMS
Merck Sharp & Dohme LLC $34.6402/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238276847 CMS
PFIZER INC. $7.1002/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228870557 CMS
E.R. Squibb & Sons, L.L.C. $8.3402/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933935 CMS
Gilead Sciences, Inc. $1.9502/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234609505 CMS
PFIZER INC. $4.3802/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228877797 CMS
Alexion Pharmaceuticals, Inc. $30.9502/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202953432 CMS
Exelixis Inc. $36.0201/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218790243 CMS
Alexion Pharmaceuticals, Inc. $33.9201/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202948338 CMS
Aveo Pharmaceuticals, Inc. $20.0001/08/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1199898644 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,369.79 197
PY2020 $10,425.35 53
PY2021 $4,671.36 92
PY2022 $9,536.82 161
PY2023 $8,076.24 193
PY2024 $13,587.41 249
PY2025 $3,923.74 152

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $96,620.75 31
PY2024 Recipient $746.00 1
PY2024 Principal investigator $131,888.56 35
PY2023 Principal investigator $417,974.29 45
PY2022 Principal investigator $85,479.23 11
PY2021 Principal investigator $524,383.39 34
PY2020 Principal investigator $1,145,676.90 254
PY2019 Principal investigator $1,538,125.60 302

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $650.00 12/22/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228713222
Principal investigator 1 PFIZER INC. $1,300.00 11/24/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228713404
Principal investigator 1 PFIZER INC. $7,152.00 11/14/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228818128
Principal investigator 1 PFIZER INC. $650.00 10/27/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228713402
Principal investigator 1 PFIZER INC. $2,384.00 10/09/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228824844
Principal investigator 1 GlaxoSmithKline, LLC. $345.00 09/26/2025 Non-covered Recipient Entity
ADVARRA
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192105034
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 09/18/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103525
Principal investigator 1 GlaxoSmithKline, LLC. $1,405.75 09/18/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103532
Principal investigator 1 PFIZER INC. $38,167.50 09/16/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228835972
Principal investigator 1 PFIZER INC. $2,384.00 09/09/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228836036
Principal investigator 1 GlaxoSmithKline, LLC. $3,800.00 08/27/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192103490
Principal investigator 1 PFIZER INC. $2,384.00 08/06/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228843601
Principal investigator 1 PFIZER INC. $1,300.00 07/29/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228713220
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 07/22/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192103495
Principal investigator 1 Karyopharm Therapeutics Inc. $2,694.00 06/20/2025 Non-covered Recipient Entity
California Cancer Assocs.for Research and Excellence
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246662824
Principal investigator 1 PFIZER INC. $2,384.00 06/06/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228852098
Principal investigator 1 GlaxoSmithKline, LLC. $1,405.75 06/05/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103519
Principal investigator 1 PFIZER INC. $2,384.00 05/14/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228857674
Principal investigator 1 PFIZER INC. $2,384.00 05/01/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228857721
Principal investigator 1 F. Hoffmann-La Roche AG $532.80 04/16/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE
Ph III GDC 199 GA101 vs GChl in CLL with comorbidities No dispute reported 06/30/2026 1211582487
Principal investigator 1 F. Hoffmann-La Roche AG $624.96 04/16/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE
Ph III GDC 199 GA101 vs GChl in CLL with comorbidities No dispute reported 06/30/2026 1211582491
Principal investigator 1 Eli Lilly and Company $76.95 04/08/2025 Non-covered Recipient Entity
CANCER CAR ASSOCIATES OF FRESNO MEDICAL GROUP
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) No dispute reported 06/30/2026 1187876155
Principal investigator 1 PFIZER INC. $1,625.00 03/31/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228840946
Principal investigator 1 PFIZER INC. $2,384.00 03/14/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228862508
Principal investigator 1 PFIZER INC. $2,384.00 02/14/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228835977
Principal investigator 1 Eli Lilly and Company $8,393.26 01/22/2025 Non-covered Recipient Entity
CANCER CAR ASSOCIATES OF FRESNO MEDICAL GROUP
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) No dispute reported 06/30/2026 1187875425
Principal investigator 1 GlaxoSmithKline, LLC. $1,405.75 01/16/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103506
Principal investigator 1 PFIZER INC. $2,384.00 01/15/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228863630
Principal investigator 1 GlaxoSmithKline, LLC. $854.83 01/09/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103501
Principal investigator 1 GlaxoSmithKline, LLC. $550.92 01/09/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,230.28 01/09/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184147345